ImportanceImpaired glucose and obesity are known characteristics of patients with PD, although it is unclear whether the dysfunction precedes or results from the neurodegeneration.ObjectiveTo assess whether glycemic traits and anthropometric traits can influence the risk of PD in 33,674 cases and 449,056 healthy controls using Mendelian randomization (MR) framework.Design, setting, and participantsWe investigated causality with a two-sample bidirectional MR approach in the European population. We used the inverse variance-weighted (IVW), weighted median (WME), and weighted mode (MBE) methods to compute effect estimates with summary statistics from available meta-analyses of genome-wide association studies (GWAS) on glycemic and anthropometric traits that used discovery cohorts. We conducted sensitivity analyses with prioritized genetic instruments that used different study designs including employment of different study cohorts and body mass index (BMI) adjusted exposures, and exclusion of overlapping samples between risk factors and outcome datasets, and potential pleiotropic genetic instruments.Main outcome and measuresPD, glycemic and anthropometric traitsResultsWe observed a risky effect of PD on fasting glucose (FG) (IVW: β = 0.0188 per log-odds of PD; 95% CI 0.0062–0.0313, p-value = 0.0055). We further observed a protective effect of PD on type 2 diabetes (T2D) (WME: OR = 0.946 per log-odds of PD; 95% CI 0.929–0.983, p-value = 0.0051). A direct causal role of waist-hip ratio (WHR) was also observed in PD (IVW OR = 0.735; 95% CI = 0.622-0.868 per 1-SD of WHR, p = 0.0003). However, the association was lost after WHR was adjusted for body mass index (BMI) (IVW OR = 0.889; 95% CI = 0.779-1.037 per 1-SD of WHR adjusted for BMI, p = 0.1429) indicating that the observed association is mediated via BMI The associations were further retained after the exclusion of overlapping UK Biobank (UKB) samples in the PD dataset.Conclusions and relevanceOur results showed that PD patients are glucose tolerant with protection against T2D. Furthermore, central obesity may be protective against PD development, independent of glucose levels. The implication of different indices of glycemic control and body fat distribution on the PD symptomatology deserves further investigation.Key pointsQuestionAre glucose and obesity associated with Parkinson’s disease?FindingsUsing bi-directional Mendelian randomization (MR) approach, and using Parkinson disease (PD) as an exposure, our study found that a 1-log odds increase in genetic predisposition to PD was associated with 0.0188 mmol/l increase in fasting glucose concentration. The genetic predisposition to PD was also associated with a 5.4% lower risk of type-2 diabetes (T2D). We found that a 1-SD increase in waist-hip ratio (WHR) was associated with a 26.5% lower risk of PD in the European population, likely to be mediated via body mass index.MeaningA strong genetic predisposition towards glucose tolerance was observed in PD patients. and PD patients are protective against T2D. Further, an increase in WHR lowers the risk of PD. Our study thereby suggests potential roles of body fat distribution and glycemic traits on PD symptomatology.